10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG / Efficace, Fabio; Huls, Gerwin A.; Kicinski, Michal; Van Der Velden, Walter JFM; Noppeney, Richard; Chantepie, Sylvain; Griskevicius, Laimonas; Neubauer, Andreas; Audisio, Ernesta; Luppi, Mario; Fuhrmann, Stephan; Foà, Robin; Crysandt, Martina; Gaidano, Gianluca; Vrhovac, Radovan; Venditti, Adriano; Posthuma, Eduardus F. M.; Candoni, Anna; Baron, Frederic; Legrand, Olivier; Mengarelli, Andrea; Vignetti, Marco; Giraut, Anne; Coens, Corneel; Suciu, Stefan; Wijermans, P. W.; Luebbert, Michael. - In: BLOOD. - ISSN 0006-4971. - 140:Supplement 1(2022), pp. 1281-1283. [10.1182/blood-2022-166544]
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
Luppi, Mario;Candoni, Anna;
2022
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
